AKT1 and osteosarcoma: For example, in osteosarcoma, TRIM22 can impact autophagy by modulating the ROS/AMPK/mTOR signaling pathway (Liu et al., 2022), while in lung cancer, it can influence epithelial‐mesenchymal transition through the AKT/GSK3β signaling pathway (Liu et al., 2022).